Test whether blocking AMPA changes ketamine’s suicide relief
Treatments studied
Part of Mental health clinical trials.
This study looks at whether an “AMPA receptor blocker” changes how ketamine affects suicidal thoughts in people with depression that hasn’t improved with usual treatments. If you qualify, you may receive ketamine and the study medicine, while continuing your regular mental health care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have depression with a high enough depression score on a structured interview
- You have current suicidal thoughts (not just past thoughts)
- Your depression symptoms have not improved after trying one or more appropriate antidepressant treatments
- You must be in an outside mental health treatment program during the study (or be willing to start and wait until you’ve been in treatment for at least 4 weeks)
- If you take depression medicines or do therapy, your current plan must be stable for at least 4 weeks and you must have a plan to keep it during the study
- You must avoid caffeine, drugs, and alcohol for one week before each ketamine infusion and be able to read and write English
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study looks at how parts of brain cells respond to ketamine in people with depression who have not improved with usual antidepressants. It may help researchers find why ketamine works for some people and not others, and who might benefit.
This Phase 4 study tests whether ongoing treatment with ketamine or esketamine can reduce suicidal thoughts in people with major depression who are at high risk. Because the study focuses on long-term maintenance, you’d receive treatment over time while being closely monitored for safety and mental health changes.
This study compares ketamine alone to ketamine combined with psychotherapy for treating depression. It may help if you have moderate to severe depression and want to see if adding talk therapy improves results.
This trial studies how ketamine affects brain circuits in people with depression compared to healthy volunteers. It involves a single infusion of ketamine and brain scans before and after.
This study tests whether ketamine (a medication) combined with a specific type of therapy called DBT can help people with treatment-resistant depression and borderline personality disorder who are having thoughts of suicide. You would receive ketamine infusions alongside structured therapy sessions over 6 months.
This early-stage study tests ketamine and looks at what brain changes may explain why it helps people with major depression that hasn’t improved with usual treatments. You may be asked to stay in the hospital and complete detailed interviews, mood rating scales, and brain imaging.
Hear when a new Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.